ATHENA-2 CAR-T

ATHENA-2 CAR-T is an investigational allogeneic, CD19-directed chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Unlike traditional allogeneic CAR-T products that typically knock out the T-cell receptor (TCR) to prevent graft-versus-host disease (GvHD), ATHENA-2 is a "TCR-reserved" therapy that maintains TCR expression to leverage tonic signaling, which is intended to enhance cell persistence and anti-tumor efficacy. The therapy utilizes CRISPR-Cas9 gene-editing technology to selectively knock out the *Power3* gene, a modification designed to improve the cells' ability to overcome host immune rejection and enhance clinical response. ATHENA-2 is currently being evaluated in Phase 1/2 clinical trials and represents an evolution of the original ATHENA CAR-T platform.

Other names

TCR-reserved Power3-KO CD19 CAR-TTCR-reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell product